Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22080484 | 0.88 | SHBG (0.33) | GAAL3MBTL1SHBGALDH1A1ESR1 | |
| SCHEMBL22080824 | 0.87 | IDH1 (0.33) | IDH1 | |
| SCHEMBL27375601 | 0.82 | SHBG (0.40) | GAACYP1A2SHBGIDH1ALDH1A1 | |
| SCHEMBL22080754 | 0.82 | SHBG (0.37) | CYP1A2SHBGIDH1ALDH1A1ESR1 | |
| SCHEMBL5185716 | 0.81 | CES2 (0.39) | NPC1RAB9ACYP1A2 | |
| SCHEMBL5185713 | 0.81 | CES2 (0.39) | NPC1RAB9ACYP1A2 | |
| SCHEMBL29809621 | 0.81 | CES2 (0.39) | NPC1RAB9ACYP1A2 | |
| SCHEMBL28041166 | 0.81 | SHBG (0.46) | GAACYP1A2SHBGIDH1ALDH1A1 | |
| SCHEMBL22080487 | 0.80 | NOS3 (0.31) | CYP3A4 | |
| SCHEMBL5185548 | 0.79 | MEN1 (0.40) | GAASHBGALDH1A1ESR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017527-A1 | NOVEL PROCEDURE FOR THE FORMATION OF 2H-BENZOTRIAZOLE BODIES AND CONGENERS | BASF SE (DE) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017527-A1 | NOVEL PROCEDURE FOR THE FORMATION OF 2H-BENZOTRIAZOLE BODIES AND CONGENERS | GABBR1, GABBR2, SULT2A1 | NPC1 2446/4885GAA 1558/4885RAB9A 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.